Marshall Wace, LLP Capricor Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 59,303 shares of CAPR stock, worth $955,371. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,303Holding current value
$955,371% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding CAPR
# of Institutions
133Shares Held
16MCall Options Held
1.73MPut Options Held
1.71M-
Vanguard Group Inc Valley Forge, PA2.28MShares$36.7 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.25MShares$36.3 Million0.17% of portfolio
-
State Street Corp Boston, MA2.21MShares$35.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.63MShares$26.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA879KShares$14.2 Million0.0% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $392M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...